D, C., V, M., R, Q., K, I., D, G., B, R., . . . G, G. (2026). Integrating nitrosamine theoretical formation into Translational Pharmaceutics: Mitigating risks during accelerated formulation development in early phase clinical studies. Journal of pharmaceutical sciences, 104434. https://doi.org/10.1016/j.xphs.2026.104434
Chicago Style (17th ed.) CitationD, Cobice, Mamidala V, Quick R, Iyoha K, Grayson-Gaunt D, Rowe B, Brooks J, and Giuliano G. "Integrating Nitrosamine Theoretical Formation into Translational Pharmaceutics: Mitigating Risks During Accelerated Formulation Development in Early Phase Clinical Studies." Journal of Pharmaceutical Sciences 2026: 104434. https://doi.org/10.1016/j.xphs.2026.104434.
MLA (9th ed.) CitationD, Cobice, et al. "Integrating Nitrosamine Theoretical Formation into Translational Pharmaceutics: Mitigating Risks During Accelerated Formulation Development in Early Phase Clinical Studies." Journal of Pharmaceutical Sciences, 2026, p. 104434, https://doi.org/10.1016/j.xphs.2026.104434.
